The Food and Drug Administration has begun a pilot program called TEMPO that provisionally allows certain medical devices that incorporate generative AI to reach patients before receiving formal marketing authorization. Rather than a permanent change to authorization standards, the program is framed in the source as an experimental pathway that lets the agency and participating companies test approaches to oversight in clinical practice.
According to the reporting, the pilot gives regulators hands-on exposure to cutting-edge technology in real-world settings. The TEMPO pilot is positioned as a way for the FDA to gain practical experience regulating AI-driven medical devices while companies deploy their products under the pilot’s provisional terms.
The source reports that four AI-driven medical devices were recently accepted into the TEMPO pilot. Two of the named participants are Cadence and Limbic. The article notes explicitly that these devices will be allowed to be released without marketing authorization under the pilot, but it does not name the other two accepted products or describe their specific functions.
The TEMPO acceptance means the selected digital health companies can make their products available to patients even though they have not completed the FDA’s normal marketing authorization process. The reporting describes this access as provisional and as part of the pilot’s design to enable real-world testing of both the technologies and the agency’s oversight processes.
One stated objective of TEMPO is to increase the number of technologies available for the Medicare ACCESS model. The Medicare ACCESS model is an experiment in payment policy intended to support technologies that help beneficiaries manage chronic conditions. By expanding the pool of available solutions, TEMPO aims to supply options that the Medicare experiment could evaluate for payment and use with patients managing long-term conditions.
The source emphasizes that TEMPO’s role in supporting Medicare ACCESS is a key rationale for allowing provisionally released devices: it is not only a regulatory exercise but also a mechanism to populate a payment model with candidate technologies.
Beyond expanding technologies for Medicare, the TEMPO pilot serves as an operational test bed for the FDA. Allowing products to operate in clinical settings before full authorization gives the agency the opportunity to observe device behavior, monitor safety and performance in practice, and adapt regulatory approaches based on real-world experience.
The article frames this as a way for regulators and industry to “experiment with AI regulation in the real world,” indicating a deliberate learning focus rather than an immediate broad relaxation of oversight. The pilot therefore appears intended to inform future regulatory policy by exposing staff to implementation challenges and device behavior outside controlled premarket studies.
The source provides several clear facts about TEMPO, but it does not include other details that readers may seek. Specifically, the article does not report the identities of the two additional accepted devices beyond Cadence and Limbic, it does not provide selection criteria used to admit devices into the pilot, and it does not describe the specific provisions, monitoring requirements, or timelines that govern how products operate under TEMPO.
The piece also does not report data on safety, effectiveness, or patient outcomes from TEMPO-participating devices, nor does it offer statements from FDA officials or company representatives within the excerpt provided. Those details were not included in the available source material.
This reporting on the FDA TEMPO pilot was published by Mario Aguilar, Health Tech correspondent for STAT, on Sept. 3, 2026. The story appears as a STAT+ exclusive, and the source notes that the full article is available to STAT+ subscribers. The coverage situates TEMPO at the intersection of FDA policy on generative AI medical devices and Medicare payment experimentation through the ACCESS model.
Because the source is a subscription-gated STAT+ article, the available excerpt focuses on the pilot’s core facts—TEMPO’s provisional market access, the inclusion of four devices including Cadence and Limbic, and the pilot’s dual goals of supporting Medicare ACCESS and enabling regulatory learning—while omitting further operational details and commentary that may appear in the full subscriber content.